Predictors of self-assessed likelihood of future drug use among Korean adults: the role of health beliefs and personality traits.

BMC Public Health

Department of Public Health, Sahmyook University, Nowon-gu Hwarang-ro 815, Seoul, 01795, Republic of Korea.

Published: April 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Substance use is a growing public health concern in South Korea. However, research on the predictive factors influencing future drug use remains limited. This study examined the self-assessed likelihood of future drug use in a sample of 3,000 Korean adults aged 19-59 years, focusing on health beliefs and personality traits as predictors. Using multiple regression analysis based on the health belief model (HBM) and selected personality traits, we explored how perceived susceptibility, self-efficacy, hope for the future, and sensation-seeking influence the likelihood of drug use. The results indicated that demographic factors such as sex, age, and income had limited predictive power. In contrast, past drug use and recent violence-related trauma significantly increased the likelihood of future drug use. Higher perceived susceptibility was associated with an increased likelihood of drug use, whereas greater self-efficacy was associated with a reduced likelihood. Among the personality traits, hope for the future was found to decrease, and sensation-seeking to increase the likelihood of drug use. This study underscores the need for interventions to enhance self-control and reduce drug accessibility. However, limitations such as reliance on self-reported data and a cross-sectional design suggest the need for longitudinal studies and culturally adapted measures in future research. These advances are crucial for validating and extending these findings, ultimately contributing to more effective drug prevention strategies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11978181PMC
http://dx.doi.org/10.1186/s12889-025-22289-zDOI Listing

Publication Analysis

Top Keywords

future drug
16
personality traits
16
likelihood future
12
likelihood drug
12
drug
10
self-assessed likelihood
8
korean adults
8
health beliefs
8
beliefs personality
8
perceived susceptibility
8

Similar Publications

Introduction: Topoisomerase (topo) II inhibitors continue to represent a promising approach in anticancer therapy, although their clinical application is hampered by drug resistance and dose limiting toxicities.

Area Covered: We performed a critical analysis of patent literature from January 2016 to January 2025 on topo II inhibitors in oncology using the online databases Espacenet, Wipo, and Google patent.

Expert Opinion: Substantial progress in the development of novel topo II inhibitors through synthetic chemistry, natural product isolation, molecular modification, and in silico screening was recorded.

View Article and Find Full Text PDF

Purpose Clear cell renal cell carcinoma (ccRCC), the dominant subtype of renal malignancy, has a rising global incidence and mortality. While surgery is the standard of care for localized cases, adjuvant therapy aims to improve outcomes in high-risk postoperative patients. To quantify the clinical value of adjuvant pharmacotherapy, this systematic review and meta-analysis assesses its effect on overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in patients with ccRCC.

View Article and Find Full Text PDF

Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus.

Drug Deliv Transl Res

September 2025

Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan, 333031, India.

Diabetes is a metabolic disorder of increasing global concern. Characterized by constantly elevated levels of glucose, severe β-cell dysfunction, and insulin resistance, it is the cause of a major burden on patients if not managed with therapeutic and lifestyle changes. The human body is slowly developing tolerance to many marketed antidiabetic drugs and the quest for the discovery of newer molecules continues.

View Article and Find Full Text PDF

Background And Objective: Sacituzumab govitecan, an anti-trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate, has been approved by both the US Food and Drug Administration and European Medicines Agency for patients with metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. Although TROP2 evaluation is not required for patient selection, survival data from the ASCENT trial show improved response rates in patients with high TROP2 expression by immunohistochemistry. However, there is no standardized testing assay for these patients.

View Article and Find Full Text PDF

Tackling microbial iron homeostasis: novel antimicrobial strategies.

Trends Pharmacol Sci

September 2025

Department of Internal Medicine II, Infectious Diseases, Immunology, Rheumatology, Medical University of Innsbruck, Innsbruck, Austria.

The escalating threat of antimicrobial resistance demands innovative therapeutic strategies beyond classical targets. Recent insights into the mechanisms of bacterial iron acquisition - ranging from siderophores and heme uptake to ferrous iron transport - have enabled new approaches to impair pathogen growth and virulence. These pathways are increasingly being harnessed for therapeutic gain.

View Article and Find Full Text PDF